Learn how RITUXAN may benefit many patients with certain types of non-Hodgkin's lymphoma (NHL):
- For initial treatment of follicular NHL (a type of low-grade NHL)RITUXAN® (rituximab) is indicated for the treatment of patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy.
-
For ongoing therapy of
low-grade NHL after CVPRITUXAN® (rituximab) is indicated for the treatment of patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy. - For treatment upon relapse of low-grade or follicular NHLRITUXAN® (rituximab) is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
-
For initial treatment of DLBCL
(a type of high-grade NHL)RITUXAN® (rituximab) is indicated for the treatment of patients with previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP or other anthracycline-based chemotherapy regimens.
Support for CaregiversGet information and materials to help you care for someone with non-Hodgkin's lymphoma.
Go to Caregiver Resources and Materials
Questions for Your DoctorWhen you discuss your lymphoma treatment options with your doctor, these questions may help you get started.
Go to Questions for Your Doctor
Living With LymphomaJoin the Living With Lymphoma community today for support, education and inspiration.
Learn more about Living With Lymphoma
INDICATIONS
RITUXAN® (rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects, some of which can be life-threatening, including: Progressive Multifocal Leukoencephalopathy (PML), infusion reactions, Tumor Lysis Syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.
Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.
Please read the Medication Guide in HTML or PDF versions for more information.
